# US 2019/0314495 A1 · Allergen desensitization method

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314495 A1
- Document ID: US20190314495A1
- Status: Published application
- Kind: A1
- Application number: 16/395,206
- Filed: 2019-04-25
- Published: 2019-10-17
- Earliest claimed: 2007-12-03
- Assignees: DBV Technologies; Assistance Publique-Hopitaux de Paris; Universite Paris Descartes
- Applicants: DBV Technologies; Assistance Publique Hôpitaux De Paris; Université Paris Descartes
- Inventors: Christophe DUPONT; Pierre-Henri BENHAMOU; Bertrand DUPONT
- Web page: https://patentgrep.com/patent/US20190314495A1

## CPC

- A61K 39/35: Allergens
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/7007: {Drug-containing films, membranes or sheets (A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence)}
- A61K 39/36: from pollen
- A61P 17/00: Drugs for dermatological disorders
- A61P 37/02: Immunomodulators
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61K 9/7023: {Transdermal patches and similar drug-containing composite devices, e.g. cataplasms (galenical aspects of iontophoretic devices A61K9/0009; microneedle arrays A61K9/0021; buccal patches A61K9/006)}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present application relates to a method for desensitization of allergic patients. More specifically it relates to an epicutaneous desensitization method, applicable to any type of allergens and of patients. The method of the invention is essentially non-invasive and does not require the use of adjuvants. Further, it may be easily applied and monitored by the actual patient.

## Claims

### Claim 1

A method for epicutaneous desensitization of a subject allergic to milk, the method comprising:
a) determining a dose of a milk allergen which causes an immune reaction on the skin of the subject upon epicutaneous application thereof;
b) epicutaneously exposing the subject to the milk allergen and generating the immune reaction in the subject by applying said dose of the milk allergen, without an adjuvant, onto an intact region of skin of the subject; and
c) repeatedly applying the milk allergen, without an adjuvant, to an intact region of the skin of the subject, at a dose, frequency or for an application time adapted to sustain the immune reaction, the exposure and sustained reaction leading to desensitization of the subject;
wherein the milk allergen is applied by a cutaneous occlusive device configured to ensure contact between the allergen and the region of skin, and wherein said dose of milk allergen is comprised between 0.1 and 1,000 μg/cm2 of a surface area of the device.

### Claim 2 (depends on 1)

The method of claim 1, further comprising visually evaluating the immune reaction.

### Claim 3 (depends on 1)

The method of claim 1, wherein the dose, frequency, or application time of the milk allergen is increased as the immune reaction decreases during the repeated applications.

### Claim 4 (depends on 1)

The method of claim 1, wherein the dose, frequency, or application time of the milk allergen is decreased as the immune reaction increases during the repeated applications.

### Claim 5 (depends on 1)

The method of claim 1, wherein the milk allergen is in powder form.

### Claim 6 (depends on 1)

The method of claim 1, wherein the immune reaction generated during the generating step is visible to a naked eye.

### Claim 7 (depends on 6)

The method of claim 6, wherein the immune reaction comprises an infiltrated erythematous lesion.

### Claim 8 (depends on 6)

The method of claim 6, wherein the immune reaction has an eczematiform aspect.

### Claim 9 (depends on 1)

The method of claim 1, wherein the device comprises a transparent backing configured to allow the immune reaction to be viewed.

### Claim 10 (depends on 9)

The method of claim 9, wherein the backing comprises a grid configured to aid in an evaluation of the immune reaction.

### Claim 11 (depends on 1)

The method of claim 1, wherein the device is removable.

### Claim 12 (depends on 1)

The method of claim 1, wherein step a) comprises determining the immune reaction of the subject generated by different doses of the milk allergen.

### Claim 13 (depends on 1)

The method of claim 1, wherein the milk allergen comprises milk proteins.

### Claim 14 (depends on 1)

The method of claim 1, wherein step a) further comprises:
determining the immune reaction of the subject generated by different forms of the milk allergen; and
selecting a form of milk allergen for the treatment based on said determination.
